Proton pump inhibitors for functional dyspepsia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Pinto Sanchez, Maria Ines ^a   Yuan, Yuhong ^a   Bercik, Premysl ^a   Moayyedi, Paul ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADVERSE EVENT; CLINICAL PROTOCOL; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; GASTROESOPHAGEAL REFLUX; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

EID: 85032653684     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011194     Document Type: Review

References (43)

1. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJ. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Alimentary Pharmacology and Therapeutics 2004;19(6):631-41.
2. Barbera R, Feinle C, Read NW. Nutrient specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Digestive Diseases and Sciences 1995;40(8):1636-41.
3. Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgraduate Medical Journal 1979;55(Suppl 1):30-2.
4. Blum AL, Talley NJ, O'Moráin C, van Zanten SV, Labenz J, Stolte M, et al.Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) study group. New England Journal of Medicine 1998;339(26):1875-81.
5. Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?. Alimentary Pharmacology and Therapeutics 2003;18(1):117-24.
6. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002;123(6):1778-85.
7. Camillieri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nature Reviews. Gastroenterology & Hepatology 2013;10(3):187-94.
8. Chen JD, Ke MY, Lin XM, Wang Z, Zhang M. Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. Alimentary Pharmacology and Therapeutics 2000;14(8):1041-7.
9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Colin-Jones DG, Bloom B, Bodemar G, Crean G, Freston J, Gugler R, et al.Management of dyspepsia: report of a working party. Lancet 1988;331(8585):576-9.
11. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: a multinational consensus document on functional gastrointestinal disorders - functional bowel disorders and functional abdominal pain. Gut 1999;45(2):ii-43.
12. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-90.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
14. Froehlich F, Gonvers JJ, Wietlisbach V, Burnand B, Hildebrand P, Schneider C, et al.Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. American Journal of Gastroenterology 2001;96(8):2329-36.
15. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows. Brozek J, Oxman A, Schünemann H, 2008.
16. Brozek J, Oxman A, Schünemann H. GraphPad Software. GraphPad Software. 5.04. La Jolla California: GraphPad Software, 2010.
17. Hamilton J, Guthrie E, Creed F, Thompson D, Tomenson B, Bennett R, et al.A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000;119(3):661-9.
18. Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. American Journal of Gastroenterology 1998;93(3):368-74.
19. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics 2002;16(9):1641-8.
20. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. International Journal of Cardiology 2013;167(3):965-74. [PUBMED: 22464478].
21. Lacy BE, Talley NJ, Locke GR 3rd, Bouras EP, DiBaise JK, El-Serag HB. Review article: current treatment options and management of functional dyspepsia. Alimentary Pharmacology and Therapeutics 2012;36(1):3-15.
22. Lacy BE, Weiser KT, Kennedy MD, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Alimentary Pharmacology & Therapeutics 2013;38(2):170-7.
23. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al.Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. New England Journal of Medicine 1998;339(26):1869-74.
24. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001960].
25. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127(5):1329-37.
26. Moayyedi P, Shelly S, Deeks JJ, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD001960.pub4].
27. Overland MK. Dyspepsia. Medical Clinics of North America 2014;98:549-64.
28. Thomson ISI ResearchSoft. Reference Manager. 12.0.3. Copenhagen: Thomson ISI ResearchSoft, 2014.
29. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
30. Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications. Alimentary Pharmacology & Therapeutics 2004;20(Suppl 6):1-10.
31. Suzuki H, Okada S, Hibi T. Proton pump inhibitors for the treatment of functional dyspepsia. Therapeutic Advances in Gastroenterology 2011;4(4):219-26. [DOI: 10.1177/1756283X11398735].
32. Talley NJ. Drug treatment of functional dyspepsia. Scandinavian Journal of Gastroenterology 1991;182:47-60.
33. Talley NJ. Functional dyspepsia--should treatment be targeted on disturbed physiology?. Alimentary Pharmacology and Therapeutics 1995;9(2):107-15.
34. Talley NJ, Meinech-Schmidt V, Pare P. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Alimentary Pharmacology and Therapeutics 1998;12(11):1055-65.
35. Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999;318(7187):833-7.
36. Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. New England Journal of Medicine 1999;341(15):1106-11.
37. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. American Journal of Gastroenterology 2005;100(10):2324-37.
38. Tett SE, Sketris I, Cooke C, van Zanten SV, Barozzi N. Differences in utilization of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. Pharmacoepidemiology and Drug Safety 2013 Apr 4 [Epub ahead of print]. [DOI: 10.1002/pds.3442].
39. Van Outryve M, De Nutte N, Van Eeghem P. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scandinavian Journal of Gastroenterology 1993;195:47-52.
40. Wang WH, Huang JQ, Zheng GF. Effects of proton pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clinical Gastroenterology and Hepatology 2007;5(2):178-85.
41. Wilhelm S, Rjater R, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Review of Clinical Pharmacology 2013;6(4):443-51.
42. Wong WM, Wong BC, Hung WK, Yee YK, Yip AW, Szeto ML, et al.Double blind, randomized, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002;51(4):502-6.
43. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139(4):115-27.